- Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion TranscriptMar 07, 2023
- AVROBIO Inc Virtual Gaucher Disease Program Update TranscriptDec 07, 2022
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- AVROBIO Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- AVROBIO Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2022
- Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) TranscriptMar 08, 2022
- AVROBIO Inc Cystinosis Update Call TranscriptFeb 09, 2022
- AVROBIO Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- AVROBIO Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 28, 2021
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- AVROBIO Inc at JMP Securities Life Sciences Virtual Conference TranscriptJun 17, 2021
- AVROBIO Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 09, 2021
- AVROBIO Inc Presents new Clinical Data from Fabry Disease, Cystinosis and Gaucher disease Type 1 Programs TranscriptFeb 08, 2021
- AVROBIO Inc at ICR Virtual Conference TranscriptJan 14, 2021
- AVROBIO Inc Virtual R&D Day TranscriptNov 17, 2020
- AVROBIO Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) TranscriptOct 13, 2020
- AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Avrobio Inc at WORLDSymposium 2020 TranscriptFeb 11, 2020
- AVROBIO Inc Announces Positive Data from Clinical Trials of AVR-RD-01- Call TranscriptJul 15, 2019
AVROBIO Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Good afternoon, everyone. My name is Gena Wang. I'm [senior] biotech analyst at the Barclays. Welcome to our fifth Gene Editing & Gene Therapy Summit. It is my great pleasure to introduce our next speaker, Geoff MacKay, Chief Executive Officer of AVROBIO. Geoff, I will hand over to you.
Thank you very much, Gena. I'll just share my slides. Be right with you. Okay. Thank you.
So it's a real honor to get to present the deck, and I'll try to be concise to make sure that we have some time for questions.
Before I begin the presentation, we'll contain forward-looking statements based on current expectations and beliefs, and I refer you to our SEC filings for further information.
The purpose of AVROBIO is to free patients from a lifetime of genetic disease. And I'll share with you today data across 4 trials, 19 patients that suggest that the ongoing data generated, to date at least, is giving
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)